Cell and gene therapy trials — The synergy of CRO and specialty logistics collaboration

Cell and gene therapies (CGTs) or advanced therapy medicinal products (ATMPs) in the EU offer new hope in treating previously untreatable illnesses, including cancers, chronic conditions, and rare diseases. This has led to a surge in innovative CGTs entering clinical trials, potentially marking a golden age for contract research organizations (CROs) as they manage complex logistical demands within the cell therapy supply chain while prioritizing investigator well-being and participant comfort.

Despite growth in the CGT field, limited approved therapies and unique logistical challenges can leave CROs inexperienced. In this white paper, developed by World Courier, a part of Cencora, in collaboration with IQVIA, we explore the crucial partnership between CROs and specialty logistics in CGT clinical trials, unveiling strategies and insights for success in this rapidly evolving field of cell therapy logistics.